HomeAMBU-B • CPH
Follow
Ambu A/S
Previous close
kr 114.35
Day range
kr 110.80 - kr 113.05
Year range
kr 65.62 - kr 126.20
Market cap
26.87B DKK
Avg Volume
509.16K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.25B | 10.78% |
Operating expense | 613.00M | 3.20% |
Net income | 92.00M | 318.18% |
Net profit margin | 7.34 | 278.35% |
Earnings per share | 0.35 | 288.89% |
EBITDA | 213.00M | 46.90% |
Effective tax rate | 23.33% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 277.00M | 121.60% |
Total assets | 6.84B | -2.40% |
Total liabilities | 1.42B | -50.87% |
Total equity | 5.42B | — |
Shares outstanding | 266.30M | — |
Price to book | 5.62 | — |
Return on assets | 4.60% | — |
Return on capital | 5.24% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 92.00M | 318.18% |
Cash from operations | 189.00M | 292.86% |
Cash from investing | -54.00M | 28.95% |
Cash from financing | -15.00M | -113.39% |
Net change in cash | 120.00M | 293.55% |
Free cash flow | 139.12M | 216.79% |
About
Ambu, or officially Ambu A/S, is a Danish company that develops, produces and markets single-use endoscopy solutions, diagnostic and life-supporting equipment to hospitals, private practices, and rescue services.
It was founded in Denmark in 1937, as Testa Laboratorium, by German engineer Holger Hesse.
The largest business areas are anesthesia, cardiology, neurology, pulmonology, urology and gastroenterology. The company's most important products are devices for artificial ventilation, single-use endoscopes and single-use electrodes for ECG tests and neurophysiological mappings. Wikipedia
Founded
1937
Website
Employees
4,600
